Pfizer Inc's quarterly revenue rose about 11 per cent, driven by sales of newer drugs and the acquisition of hospital products company Hospira last year.
The largest US drug maker's revenue rose to $13.15 billion in the second quarter, from $11.85 billion a year earlier.
The company's net income fell to $2.02 billion, or 33 cents per share, from $2.63 billion, or 42 cents per share.
Pfizer in April terminated its $160 billion tax inversion deal to acquire Irish drug maker Allergan Plc.
Pfizer Inc's quarterly revenue rose about 11 per cent, driven by sales of newer drugs and the acquisition of hospital products company Hospira last year.
The largest US drug maker's revenue rose to $13.15 billion in the second quarter, from $11.85 billion a year earlier.
The company's net income fell to $2.02 billion, or 33 cents per share, from $2.63 billion, or 42 cents per share.
Pfizer in April terminated its $160 billion tax inversion deal to acquire Irish drug maker Allergan Plc.
Sign Up with Google
RECOMMENDED FOR YOU
POPULAR